Johnson & Johnson (NYSE:JNJ) Shares Bought by Daymark Wealth Partners LLC

Daymark Wealth Partners LLC increased its stake in Johnson & Johnson (NYSE:JNJ) by 3.1% during the fourth quarter, HoldingsChannel.com reports. The fund owned 310,032 shares of the company’s stock after buying an additional 9,279 shares during the period. Johnson & Johnson makes up approximately 1.5% of Daymark Wealth Partners LLC’s holdings, making the stock its 17th biggest position. Daymark Wealth Partners LLC’s holdings in Johnson & Johnson were worth $44,837,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds also recently modified their holdings of JNJ. Advisory Alpha LLC increased its stake in Johnson & Johnson by 7.2% in the 4th quarter. Advisory Alpha LLC now owns 7,216 shares of the company’s stock worth $1,044,000 after purchasing an additional 485 shares in the last quarter. Corepath Wealth Partners LLC boosted its holdings in shares of Johnson & Johnson by 3.7% in the fourth quarter. Corepath Wealth Partners LLC now owns 1,985 shares of the company’s stock worth $287,000 after buying an additional 70 shares during the period. Bourne Lent Asset Management Inc. increased its position in shares of Johnson & Johnson by 1.4% in the fourth quarter. Bourne Lent Asset Management Inc. now owns 14,366 shares of the company’s stock worth $2,078,000 after acquiring an additional 200 shares in the last quarter. XML Financial LLC raised its holdings in shares of Johnson & Johnson by 0.6% during the fourth quarter. XML Financial LLC now owns 69,537 shares of the company’s stock valued at $10,057,000 after acquiring an additional 420 shares during the period. Finally, Genesis Private Wealth LLC purchased a new stake in shares of Johnson & Johnson in the 4th quarter valued at approximately $308,000. 69.55% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

Several analysts have issued reports on JNJ shares. Leerink Partners cut their target price on shares of Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research note on Thursday. Guggenheim increased their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a research note on Wednesday, November 6th. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $215.00 target price on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Bank of America reduced their price target on shares of Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research report on Thursday. Finally, Citigroup lowered their price objective on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Nine investment analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, Johnson & Johnson presently has a consensus rating of “Moderate Buy” and a consensus target price of $170.06.

Insider Activity at Johnson & Johnson

In related news, Director Mark A. Weinberger bought 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the purchase, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $146.76 on Friday. The firm has a market capitalization of $353.34 billion, a PE ratio of 22.07, a PEG ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $168.85. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The firm’s fifty day simple moving average is $147.99 and its 200 day simple moving average is $155.98.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. The business had revenue of $22.52 billion for the quarter, compared to analyst estimates of $22,438,500 billion. During the same period in the previous year, the company posted $2.29 earnings per share. The firm’s revenue for the quarter was up 5.3% on a year-over-year basis. On average, sell-side analysts anticipate that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. This represents a $4.96 dividend on an annualized basis and a yield of 3.38%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio (DPR) is currently 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.